Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
PHASE4Active, not recruitingINTERVENTIONAL
Enrollment
12
Participants
Timeline
Start Date
February 16, 2022
Primary Completion Date
January 15, 2024
Study Completion Date
July 15, 2026
Conditions
Psoriasis VulgarisPsoriasisSkin DiseasesSkin Diseases, PapulosquamousSkin and Connective Tissue Diseases
Interventions
DRUG
Enstilar
Topical foam
DRUG
Placebo-vehicle
Topical foam
Trial Locations (1)
8200
Department of Dermatology, Aarhus N
All Listed Sponsors
lead
Aarhus University Hospital
OTHER
NCT05185258 - Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study | Biotech Hunter | Biotech Hunter